Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.

Acne Scars - Mixed Atrophic and Hypertrophic Clinical Trial

Official title:

Open-label, Safety, and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER: Glass 1540nm Laser Module in the Treatment of Acne Scars.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06102343
• Other study ID #: ALM-HAR-CLS-23-01
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2024
• Est. completion date: January 1, 2025

Study information

• Verified date: October 2023
• Source: Alma Lasers
• Contact: Natalie Dror, PhD
• Phone: +972528264282
• Email: natalie.dror[@]almalasers.co.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The ClearSkin module, Er: Glass 1540nm, is largely used in the treatment of acne vulgaris and acne scars. The non-ablative ER:Glass 1540 nm laser deeply penetrates the skin, causing thermal damage to the sebaceous glands, destroying P. acnes bacteria and reducing sebum production, while leaving the epidermis intact. The integrated vacuum mechanism extracts accumulated sebaceous material from the pores, while contact cooling protects the skin, reducing pain and allowing for safer and more effective treatment of the sebaceous glands within the dermis. Based on this background, the investigators have considered a pilot study aimed at assessing the efficacy and safety of the ClearSkin Module in treating subjects with facial acne scars.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 41
• Est. completion date: January 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Men or women aged 18 to 50 years
• Presence of mild to moderate facial acne scars (according to Goodman & Baron's scale)
• Subjects in reasonably good general health, according to the Investigator's judgment;
• Subjects who agree to avoid tanning during the entire investigational period;
• Subjects who agree to avoid any other facial procedure during the entire investigational period; including but not limited to: injectables or threads, peeling of any kind, dermabrasion, facial hair removal, or application of any cosmeceutical/pharmaceutical without the consent from the PI only.
• Subjects able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgment.
• Subjects willing to sign an informed consent, consent to use their photos for future scientific or marketing purposes, according to the sponsor's needs.

Exclusion Criteria:

• Subjects with active infections
• Subjects with a history of keloid scarring or hypertrophic scar formation
• Subjects with previous medical treatment of the area, or oral retinoid drug prescribed within the past six months
• Subjects who have been tanning within the past 30 days;
• Previous surgical treatment of the area selected for the treatment with the investigational device;
• Subjects with any inflammatory skin condition e.g., eczema, active herpes simplex, etc. at the treatment site;
• Subjects with the presence of tattoos at the treatment site
• Subjects with skin cancer or any other cancer and/or any cancer drug therapy (such as ducabaxine, fluorouracil, methotrexate, etc.)
• Subjects with history of autoimmune disorder or evidence of immunosuppression;
• Subjects with collagen vascular diseases
• Subjects with thrombocytopenia
• Subjects with peripheral vascular disease
• Subjects with Melasma
• Pregnant or lactating subjects

Related Conditions & MeSH terms

• Acne Scars - Mixed Atrophic and Hypertrophic
• Hypertrophy

Intervention

Device:
• Alma Harmony
Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.

Locations

Country	Name	City	State
Portugal	Up Clinic	Lisboa

Sponsors (1)

Lead Sponsor	Collaborator
Alma Lasers

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of at least 6 points in Goodman Baron's score at 3-month follow-up visit compared to baseline.	comparison of acne scars' Goodman Baron's score at baseline with acne scars' Goodman Baron's score at 3-month follow-up visit compared to baseline.	throughout the study, up to 1 year.
Secondary	Improvement in the treated facial acne scars after ClearSkin according to the General Aesthetic Improvement Scale (GAIS), at the 3-month follow-up visit compared to baseline.	70% of participants will demonstrate any improvement in the treated facial acne scars after ClearSkinTM according to the General Aesthetic Improvement Scale (GAIS), at the 3-month follow-up visit compared to baseline, as evaluated by three blinded assessors. The evaluation will be performed by means of the examination of the photography of treated facial acne scars performed using 2D photographs.	throughout the study, up to 1 year.
Secondary	Improvement in the treated facial acne scars after ClearSkin according to the General Aesthetic Improvement Scale (GAIS), at the 1-month follow-up visit compared to baseline.	Improvement in aesthetic appearance of the treated facial acne scars, as assessed by the principal investigator according to the General Aesthetic Improvement Scale (GAIS) at the 1-month follow-up visit compared to baseline. The evaluation will be performed by means of the examination of the photography of all treated facial acne scars performed using 2D photographs.	throughout the study, up to 1 year.
Secondary	Improvement in skin texture of the treated facial acne scars.	Improvement in skin texture of the treated facial acne scars, as evaluated by the 3D pictures taken at the 1- and 3-month follow-up visits compared to baseline.	throughout the study, up to 1 year.
Secondary	Participant's satisfaction rates	Participant's satisfaction with treatment with the investigational devices using a 5-point Likert scale, at 1- and 3-month follow-up visits.	throughout the study, up to 1 year.
Secondary	Adverse Events frequency & intensity.	Adverse Events frequency & intensity, occurring at any time during the trial or follow-up periods.	throughout the study, up to 1 year.
Secondary	Pain level rates	Pain level using NPRS, as evaluated at each treatment visit at the end of each treatment session.	throughout the study, up to 1 year.